These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23397500)

  • 41. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
    Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
    J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
    Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies.
    Carella AM; Berman E; Maraone MP; Ganzina F
    Haematologica; 1990; 75(2):159-69. PubMed ID: 2192943
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.
    DeAngelo DJ; Walker AR; Schlenk RF; Sierra J; Medeiros BC; Ocio EM; Röllig C; Strickland SA; Thol F; Valera SZ; Dasgupta K; Berkowitz N; Stuart RK
    Leuk Res; 2019 Oct; 85():106197. PubMed ID: 31541945
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
    Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.
    Advani AS; McDonough S; Copelan E; Willman C; Mulford DA; List AF; Sekeres MA; Othus M; Appelbaum FR
    Br J Haematol; 2014 Oct; 167(2):233-7. PubMed ID: 25039477
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
    Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Prendiville J; Glynne P; Allford S; Mackay H; Treleaven J
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):18-23. PubMed ID: 8916312
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
    Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
    Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.
    Zhao H; Xu L; Yang Y; Shao J; Chen P; Dong X; Gu L; Li D
    Acta Haematol; 2017; 137(4):195-200. PubMed ID: 28445872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
    Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
    J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A Retrospective Study on the Efficacy and Safety of Idarubicin Combined with High-Dose Cytarabine Consolidation in Patients with Acute Myeloid Leukemia over 60 Years of Age in First Remission].
    Cao J; Ye YZ; Zheng XY; Chen Y; Luo LT; Zheng J; Yang T; Hu JD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):671-676. PubMed ID: 37356925
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
    Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Martínez-Cuadrón D; Boluda B; Martínez P; Bergua J; Rodríguez-Veiga R; Esteve J; Vives S; Serrano J; Vidriales B; Salamero O; Cordón L; Sempere A; Jiménez-Ubieto A; Prieto-Delgado J; Díaz-Beyá M; Garrido A; Benavente C; Pérez-Simón JA; Moscardó F; Sanz MA; Montesinos P;
    Ann Hematol; 2018 May; 97(5):763-772. PubMed ID: 29392425
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment.
    Bermúdez A; Pérez-Vázquez G; Insunza A; Baro J; Colorado M; Conde E; Díez-Gallarreta Z; Gutiérrez ML; López-Duarte M; Olalla I; Sanroma P; Yañez L; Iriondo A; Richard C
    Am J Hematol; 2012 Jan; 87(1):42-4. PubMed ID: 22015963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
    Wiernik PH; Banks PL; Case DC; Arlin ZA; Periman PO; Todd MB; Ritch PS; Enck RE; Weitberg AB
    Blood; 1992 Jan; 79(2):313-9. PubMed ID: 1730080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
    Garcia-Manero G; Tambaro FP; Bekele NB; Yang H; Ravandi F; Jabbour E; Borthakur G; Kadia TM; Konopleva MY; Faderl S; Cortes JE; Brandt M; Hu Y; McCue D; Newsome WM; Pierce SR; de Lima M; Kantarjian HM
    J Clin Oncol; 2012 Jun; 30(18):2204-10. PubMed ID: 22585696
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.
    Bauer KS; Karp JE; Garimella TS; Wu S; Tan M; Ross DD
    Leuk Res; 2005 Mar; 29(3):263-71. PubMed ID: 15661261
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
    Tsai HJ; Hsiao HH; Hsu YT; Liu YC; Kao HW; Liu TC; Cho SF; Feng X; Johnston A; Bomalaski JS; Kuo MC; Chen TY
    Cancer Med; 2021 May; 10(9):2946-2955. PubMed ID: 33787078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Idarubicin: a pharmacoeconomic evaluation of its use in adult patients with acute myeloid leukaemia.
    Whittington R; Goa KL
    Pharmacoeconomics; 1993 Oct; 4(4):287-307. PubMed ID: 10146918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.